Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Three-Arm, Open-Label, Endpoint-Blinded Randomized Controlled Trial to Evaluate the Optimal Infusion Duration of Early Tirofiban Treatment After Intravenous Thrombolysis in Patients With Acute Ischemic Stroke (INSTANT-2)

NCT07842185 is registered in ClinicalTrials.gov with Xinqiao Hospital of Chongqing as lead sponsor.

NCT NCT07842185
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07842185 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Three-Arm, Open-Label, Endpoint-Blinded Randomized Controlled Trial to Evaluate the Optimal Infusion Duration of Early Tirofiban Treatment After Intravenous Thrombolysis in Patients With Acute Ischemic Stroke (INSTANT-2)
Lead sponsor
Xinqiao Hospital of Chongqing
Phase
Phase 2/3
Overall status
Not yet recruiting
Start date
November 19, 2026
Completion date
May 8, 2031
Enrollment
1,482 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

acute ischemic stroke